Publication
Case Report: Specific ABL-Inhibitor Imatinib Is an Effective Targeted Agent as the First Line Therapy to Treat B-Cell Acute Lymphoblastic Leukemia With a Cryptic NUP214::ABL1 Gene Fusion.
Authors not recorded
Pathol Oncol Res2022PMID 36172171PMC9510372stubpubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
No abstract stored. Read on PubMed
Linked entities
Linked entities (4)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 4
- cancerB Lymphoblastic Leukemia/Lymphomacivic_curation1.00
- drugImatinib Mesylatecivic_curation1.00
- geneABL1civic_curation1.00
- variantABL1 Fusioncivic_curation1.00
Curated evidence
Evidence citing this paper (1)
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 36172171
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| ABL1 Fusion1 | ||||||||
| Imatinib Mesylate | B Lymphoblastic Leukemia/LymphomaCURATED_BROADER | Predictive | C | Supports Sensitivity Response | 4 | accepted | EID12218A 15-year-old male was diagnosed with B-cell ALL with a normal male karyotype by microarray (no aberrations >5Mb), normal FISH (including BCR::ABL1 and ABL1 breakapart) and aberrant phenotype B-lympho… (full text at CIViC) PMID 36172171 · Stukaite-Ruibiene et al., 2022 · Open in CIViC | civic |